Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic
Authors:
Open Access
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Clinical Medicine
- Vol. 20 (3) , 256-261
Abstract
Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be ‘shielded’. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England.Keywords
This publication has 33 references indexed in Scilit:
- Infection Risk and Safety of Corticosteroid UseRheumatic Disease Clinics of North America, 2016
- Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipientsCochrane Database of Systematic Reviews, 2015
- Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort StudyArthritis & Rheumatology, 2015
- Serious infections in a population‐based cohort of 86,039 seniors with rheumatoid arthritisArthritis Care & Research, 2012
- Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatmentArthritis & Rheumatism, 2012
- Immune Modulation with Sulfasalazine Attenuates Immunopathogenesis but Enhances Macrophage-Mediated Fungal Clearance during Pneumocystis PneumoniaPLOS Pathogens, 2010
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010
- Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- SARS: Systematic Review of Treatment EffectsPLOS Medicine, 2006
- British Society for Rheumatology Biologics RegisterAnnals of the Rheumatic Diseases, 2003